Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration ...

Sanofi (SNY) announced the immediate adoption of influenza strains selected by the Food and Drug Administration to advance the manufacturing ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

Attorney General Aaron M. Frey announced a settlement agreement with Sanofi-Aventis U.S. LLC after scrutiny over the ...

Under the settlement, Mainers who are uninsured or have commercial health insurance will be eligible to purchase monthly ...

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target of ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to ...

Sanofi SA has described Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of allergy, pain, dermatological and inflammatory disorders.

South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...